Table 2.

Patient Outcomes by 10 Years According to Protocol-Assigned Therapy

End Point	8-Week AS → Radiotherapy + AS (n = 752)		28-Week AS → Radiotherapy + AS (n = 737)		Hazard Ratio*	95% CI	P
	No. of Events	10-Year Rate (%)	No. of Events	10-Year Rate (%)
Overall survival	230	66	220	67	0.95	0.79 to 1.15	.62
Intermediate risk	188	68	182	68	0.97	0.79 to 1.19	.75
Single factor	84	73	96	68	1.18	0.88 to 1.59	.26
Multiple factors	104	62	86	67	0.79	0.60 to 1.19	.11
High risk	39	58	38	61	0.97	0.62 to 1.51	.88
Disease-specific survival	30	95	24	96	0.81	0.48 to 1.39	.45
Intermediate risk	28	95	21	96	0.76	0.43 to 1.33	.33
Single factor	11	96	9	97	0.81	0.34 to 1.95	.64
Multiple factors	17	94	12	95	0.72	0.34 to 1.50	.38
High risk	2	97	3	97	1.61	0.28 to 9.29	.59
Disease-free survival
ASTRO (3 increases)	552	24	546	23	0.96	0.85 to 1.08	.47
ASTRO-RTOG	389	45	370	45	0.94	0.81 to 1.08	.37
Distant metastasis	38	6	40	6	1.07	0.68 to 1.66	.80
Intermediate risk	35	6	33	6	0.95	0.59 to 2.36	.84
Single factor	12	4	13	4	1.08	0.50 to 1.53	.84
Multiple factors	23	8	20	8	0.88	0.48 to 1.60	.67
High risk	3	4	7	7	2.44	0.63 to 9.52	.20
Locoregional progression	42	6	27	4	0.65	0.40 to 1.05	.07
Biochemical failure
ASTRO (3 increases)	409	56	428	59	1.02	0.89 to 1.17	.74
ASTRO-RTOG	192	27	185	27	0.97	0.79 to 1.19	.77
Intermediate risk	166	27	151	26	0.90	0.72 to 1.12	.35
Single factor	74	23	73	23	1.00	0.72 to 1.38	.99
Multiple factors	92	32	78	29	0.82	0.60 to 1.11	.20
High risk	24	23	32	31	1.45	0.86 to 2.46	.16
Second biochemical failure†	65	10	59	9	0.91	0.64 to 1.30	.62
Salvage therapy	161	22	151	22	0.94	0.76 to 1.18	.62

Abbreviations: AS, androgen suppression; ASTRO, American Society for Radiation Oncology; RTOG, Radiation Therapy Oncology Group.

^*Hazard ratios for disease-free and overall survival were determined using Cox proportional hazards regression; all others were determined using Fine-Gray competing risks hazards regression.

^†Prostate-specific antigen increase > 1.0 ng/mL on ≥ two consecutive occasions after salvage AS started.